Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome

M. L. Markel, E. N. Prystowsky, J. J. Heger, W. M. Miles, N. Fineberg, D. P. Zipes

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Encainide is a newly released type Ic antiarrhythmic agent which, when taken orally, prolongs AV nodal conduction time, His-Purkinje conduction time, and refractoriness in the atrium, ventricle, and accessory pathways. Thirty-three patients with drug resistant supraventricular tachycardias associated with WPW were treated with oral encainide ranging from 100 mg to 300 mg daily (mean 187 mg) with EPS performed pre- and post-drug treatment. Long-term follow-up (mean 26.4 months) revealed overall favorable response to therapy in 24/33 patients (73%). Side effects were not significant. Encainide appears to be an effective drug for these patients.

Original languageEnglish (US)
Pages (from-to)261-265
Number of pages5
JournalJournal of Electrophysiology
Volume1
Issue number3
StatePublished - Jan 1 1987

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome'. Together they form a unique fingerprint.

  • Cite this

    Markel, M. L., Prystowsky, E. N., Heger, J. J., Miles, W. M., Fineberg, N., & Zipes, D. P. (1987). Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. Journal of Electrophysiology, 1(3), 261-265.